Phase 2/3 study launching of targeted therapy BT8009 in urothelial carcinoma
BT8009 targets the tumor antigen Nectin-4, which has elevated expression levels in urothelial cancer.
Adjuvant pembrolizumab DFS benefit in ccRCC sustained across disease subgroups
The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.
Study explores use of imaging mass cytometry to identify therapeutic targets in kidney cancer
Researchers may be able to use imaging mass cytometry to capture and classify the tumor-immune evasion cell networks in clear cell renal cell carcinoma.
Bladder-sparing trimodal therapy yields similar results as radical cystectomy in MIBC
The 5-year metastasis-free survival rate was 75% with trimodality therapy vs 74% with radical cystectomy.
Adding short-term ADT to dose-escalated RT does not improve survival in prostate cancer
The addition of STAD did, however, improve secondary end points, including metastases rates, prostate cancer-specific mortality, and PSA failure.
Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma
The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
Study yields genetic clues to identifying aggressive prostate cancer in men of African ancestry
Researchers identified 9 novel susceptibility loci for prostate cancer, 7 of which were substantially more prevalent in patients of African ancestry.
Long-Term data sustain efficacy of lenvatinib plus pembrolizumab in kidney cancer
“As a whole, the benefits of the lenvatinib plus pembrolizumab combination proved to be durable, statistically significant, and clinically meaningful,” said senior author Camillo Porta, MD.
Nivolumab/cabozantinib shows improvements in long-term survival for RCC
Median progression-free survival in the intent-to-treat population by blinded independent central review was 16.6 months (95% CI, 12.8-19.8) with nivolumab plus cabozantinib vs 8.4 months (95% CI, 7.0-9.7) with sunitinib (HR, 0.58; 95% CI, 0.48-0.71).
Combination of vorolanib and everolimus shows strong activity in renal cell carcinoma
Published results from the phase 3 CONCEPT study showed improved outcomes with the combination compared with either agent alone.
Novel targeted therapy BT8009 granted FDA Fast Track Designation for urothelial cancer
Novel targeted therapy BT8009 granted FDA Fast Track Designation for urothelial cancer.
Batiraxcept granted FDA Fast Track Designation for renal cell carcinoma
The FDA’s Fast Track Designation is designed to expedite the review and development of novel treatments that will fill an unmet medical need.
Potential biomarkers emerge for 177Lu-PSMA-617 in metastatic prostate cancer
177Lu-PSMA-617 is approved by the FDA for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.
Targeted agent rogaratinib noninferior to chemo in FGFR+ advanced urothelial carcinoma
The findings are from the phase 2/3 FORT-1 study published in the Journal of Clinical Oncology.
SBRT safety noninferior to conventional radiotherapy in prostate cancer
The trial prospectively included a subgroup analysis comparing patients who received SBRT using robotic non-coplanar radiotherapy (CyberKnife) compared with conventional linear accelerator.
2 Clarke Drive Cranbury, NJ 08512